Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health ImpactRheumnow PodcastEarly Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact by Dr. Cush...254 days agoEarly Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health ImpactRheumnow Podcast0:00 / 0:00Read the original at soundcloud.comUse this feed in your RSS readerCopy the publisher’s public feed URL, or build an OPML reading list for another reader.Copy RSS URL Open RSS feed · Find feeds & export OPMLKeep up with this sourceFollow this sourceKeep this source in your dashboard and return to its latest articles. Email alerts are managed separately in Settings.FetchFeeds groups articles by feed so you can follow sources, compare coverage, and save stories for later.Back to all articles from Rheumnow PodcastMore from this feedChoose another story from Rheumnow Podcast.Emergencies, Independence & Hemorrhage (1.23.2026)RheumNow Live Preview (1.30.2026)DERM on RheumNow PODCAST (January 2026)ANA Pollution (2.06.2026)2026 Resolutions (1.9.2026)APP Podcast Series Part OneAPP Podcast Series Part Two2025 Rheumatology Year in Review (1.16.26)